Literature DB >> 24746818

Isolation and molecular characterization of circulating melanoma cells.

Xi Luo1, Devarati Mitra2, Ryan J Sullivan3, Ben S Wittner4, Anya M Kimura4, Shiwei Pan4, Mai P Hoang5, Brian W Brannigan4, Donald P Lawrence3, Keith T Flaherty3, Lecia V Sequist3, Martin McMahon6, Marcus W Bosenberg7, Shannon L Stott8, David T Ting3, Sridhar Ramaswamy3, Mehmet Toner9, David E Fisher10, Shyamala Maheswaran11, Daniel A Haber12.   

Abstract

Melanoma is an invasive malignancy with a high frequency of blood-borne metastases, but circulating tumor cells (CTCs) have not been readily isolated. We adapted microfluidic CTC capture to a tamoxifen-driven B-RAF/PTEN mouse melanoma model. CTCs were detected in all tumor-bearing mice and rapidly declined after B-RAF inhibitor treatment. CTCs were shed early from localized tumors, and a short course of B-RAF inhibition following surgical resection was sufficient to dramatically suppress distant metastases. The large number of CTCs in melanoma-bearing mice enabled a comparison of RNA-sequencing profiles with matched primary tumors. A mouse melanoma CTC-derived signature correlated with invasiveness and cellular motility in human melanoma. CTCs were detected in smaller numbers in patients with metastatic melanoma and declined with successful B-RAF-targeted therapy. Together, the capture and molecular characterization of CTCs provide insight into the hematogenous spread of melanoma.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24746818      PMCID: PMC4079008          DOI: 10.1016/j.celrep.2014.03.039

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  34 in total

Review 1.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

2.  Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors.

Authors:  Edward H Cho; Marco Wendel; Madelyn Luttgen; Craig Yoshioka; Dena Marrinucci; Daniel Lazar; Ethan Schram; Jorge Nieva; Lyudmila Bazhenova; Alison Morgan; Andrew H Ko; W Michael Korn; Anand Kolatkar; Kelly Bethel; Peter Kuhn
Journal:  Phys Biol       Date:  2012-02-03       Impact factor: 2.583

3.  Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.

Authors:  Amanda Pfaff Smith; Keith Hoek; Dorothea Becker
Journal:  Cancer Biol Ther       Date:  2005-09-09       Impact factor: 4.742

4.  Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.

Authors:  Leila Khoja; Paul Lorigan; Cong Zhou; Matthew Lancashire; Jessica Booth; Jeff Cummings; Raffaele Califano; Glen Clack; Andrew Hughes; Caroline Dive
Journal:  J Invest Dermatol       Date:  2012-12-06       Impact factor: 8.551

5.  A gene expression signature of invasive potential in metastatic melanoma cells.

Authors:  Aaron R Jeffs; Amy C Glover; Lynn J Slobbe; Li Wang; Shujie He; Jody A Hazlett; Anshul Awasthi; Adele G Woolley; Elaine S Marshall; Wayne R Joseph; Cristin G Print; Bruce C Baguley; Michael R Eccles
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

6.  Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.

Authors:  Sojun Hoshimoto; Tatsushi Shingai; Donald L Morton; Christine Kuo; Mark B Faries; Kelly Chong; David Elashoff; He-Jing Wang; Robert M Elashoff; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

7.  Gene expression and the biological phenotype of papillary thyroid carcinomas.

Authors:  L Delys; V Detours; B Franc; G Thomas; T Bogdanova; M Tronko; F Libert; J E Dumont; C Maenhaut
Journal:  Oncogene       Date:  2007-07-09       Impact factor: 9.867

8.  In vivo switching of human melanoma cells between proliferative and invasive states.

Authors:  Keith S Hoek; Ossia M Eichhoff; Natalie C Schlegel; Udo Döbbeling; Nikita Kobert; Leo Schaerer; Silvio Hemmi; Reinhard Dummer
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

9.  Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells.

Authors:  Daniel Ramsköld; Shujun Luo; Yu-Chieh Wang; Robin Li; Qiaolin Deng; Omid R Faridani; Gregory A Daniels; Irina Khrebtukova; Jeanne F Loring; Louise C Laurent; Gary P Schroth; Rickard Sandberg
Journal:  Nat Biotechnol       Date:  2012-08       Impact factor: 54.908

10.  Efficient tumour formation by single human melanoma cells.

Authors:  Elsa Quintana; Mark Shackleton; Michael S Sabel; Douglas R Fullen; Timothy M Johnson; Sean J Morrison
Journal:  Nature       Date:  2008-12-04       Impact factor: 49.962

View more
  55 in total

Review 1.  Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.

Authors:  Joshua M Jackson; Małgorzata A Witek; Joyce W Kamande; Steven A Soper
Journal:  Chem Soc Rev       Date:  2017-07-17       Impact factor: 54.564

2.  Surfactant functionalization induces robust, differential adhesion of tumor cells and blood cells to charged nanotube-coated biomaterials under flow.

Authors:  Michael J Mitchell; Carlos A Castellanos; Michael R King
Journal:  Biomaterials       Date:  2015-04-17       Impact factor: 12.479

Review 3.  Biomarkers in melanoma: where are we now?

Authors:  Douglas B Johnson; Ryan J Sullivan
Journal:  Melanoma Manag       Date:  2014-12-04

4.  One step antibody-mediated isolation and patterning of multiple cell types in microfluidic devices.

Authors:  Danny Bavli; Elishai Ezra; Daniel Kitsberg; Margarita Vosk-Artzi; Shashi K Murthy; Yaakov Nahmias
Journal:  Biomicrofluidics       Date:  2016-03-21       Impact factor: 2.800

5.  Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.

Authors:  Tara C Gangadhar; Samantha L Savitch; Stephanie S Yee; Wei Xu; Alexander C Huang; Shannon Harmon; David B Lieberman; Devon Soucier; Ryan Fan; Taylor A Black; Jennifer J D Morrissette; Neeraj Salathia; Jill Waters; Shile Zhang; Jonathan Toung; Paul van Hummelen; Jian-Bing Fan; Xiaowei Xu; Ravi K Amaravadi; Lynn M Schuchter; Giorgos C Karakousis; Wei-Ting Hwang; Erica L Carpenter
Journal:  Pigment Cell Melanoma Res       Date:  2017-10-23       Impact factor: 4.693

Review 6.  CTC clusters in cancer progression and metastasis.

Authors:  Anna Fabisiewicz; Ewa Grzybowska
Journal:  Med Oncol       Date:  2016-12-23       Impact factor: 3.064

7.  Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs.

Authors:  Monika Vishnoi; Debasish Boral; Haowen Liu; Marc L Sprouse; Wei Yin; Debalina Goswami-Sewell; Michael T Tetzlaff; Michael A Davies; Isabella C Glitza Oliva; Dario Marchetti
Journal:  Cancer Res       Date:  2018-07-19       Impact factor: 12.701

8.  Immobilized surfactant-nanotube complexes support selectin-mediated capture of viable circulating tumor cells in the absence of capture antibodies.

Authors:  Michael J Mitchell; Carlos A Castellanos; Michael R King
Journal:  J Biomed Mater Res A       Date:  2015-03-30       Impact factor: 4.396

9.  Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Authors:  J Zachary Sanborn; Jongsuk Chung; Elizabeth Purdom; Nicholas J Wang; Hojabr Kakavand; James S Wilmott; Timothy Butler; John F Thompson; Graham J Mann; Lauren E Haydu; Robyn P M Saw; Klaus J Busam; Roger S Lo; Eric A Collisson; Joe S Hur; Paul T Spellman; James E Cleaver; Joe W Gray; Nam Huh; Rajmohan Murali; Richard A Scolyer; Boris C Bastian; Raymond J Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-18       Impact factor: 11.205

Review 10.  Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.

Authors:  Sharon K Huang; Dave S B Hoon
Journal:  Mol Oncol       Date:  2015-12-17       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.